PDCD1 and hepatocellular carcinoma: Programmed death 1/programmed death 1 ligand 1 antibody (PD-1/L1 antibody) combined with anti-angiogenic agents such as atezolizumab plus bevacizumab were recommended as the preferred first-line treatment for unresectable HCC (3–6).